Joseph Lyssikatos Sells 7,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 7,000 shares of the company’s stock in a transaction on Friday, September 19th. The shares were sold at an average price of $19.39, for a total transaction of $135,730.00. Following the completion of the transaction, the insider owned 933,188 shares of the company’s stock, valued at approximately $18,094,515.32. The trade was a 0.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $19.20 on Thursday. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03. The firm has a market capitalization of $1.14 billion, a P/E ratio of -9.60 and a beta of 0.89. The company’s fifty day moving average price is $19.95 and its 200 day moving average price is $19.63.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Trading of Enliven Therapeutics

Several hedge funds have recently made changes to their positions in the company. Commodore Capital LP increased its stake in shares of Enliven Therapeutics by 0.4% during the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after acquiring an additional 17,809 shares during the period. Geode Capital Management LLC boosted its holdings in Enliven Therapeutics by 7.8% in the 2nd quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock valued at $17,711,000 after purchasing an additional 63,580 shares in the last quarter. TCG Crossover Management LLC acquired a new position in Enliven Therapeutics during the 2nd quarter worth approximately $9,990,000. Duquesne Family Office LLC purchased a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $9,288,000. Finally, Franklin Resources Inc. lifted its holdings in shares of Enliven Therapeutics by 2,029.3% in the 2nd quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock valued at $8,631,000 after buying an additional 410,034 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

ELVN has been the topic of a number of recent research reports. The Goldman Sachs Group began coverage on shares of Enliven Therapeutics in a report on Monday, June 16th. They issued a “buy” rating and a $37.00 target price on the stock. HC Wainwright upped their target price on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, July 2nd. Finally, Robert W. Baird raised their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, June 16th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, Enliven Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.